TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06930677: A Prospective, Single-arm, Multinational, Multi-center, Clinical Study to Evaluate the Performance and Safety of Musculoskeletal Embolization Using NBGM200 in Patients With Knee Degenerative Osteoarthritis

Sponsor: Next Biomedical Co., Ltd. · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 72 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$6,106,500

Rescue Site Savings

+$4,036,500

Unlock Full NCT06930677 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06930677 Rescue Dossier →